Cyclosporine (generic), Neoral Newswire

Cyclosporine (generic), Neoral Newswire

Comprehensive Real-Time News Feed for Cyclosporine (generic), Neoral.

Results 1 - 20 of 360 in Cyclosporine (generic), Neoral

  1. Financial Review: SCYNEXISRead the original story w/Photo

    Friday | IntersportsWire

    SCYNEXIS and Immune Pharmaceuticals are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings. SCYNEXIS has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

    Comment?

  2. Comparing Immune PharmaceuticalsRead the original story w/Photo

    Friday Aug 18 | IntersportsWire

    Immune Pharmaceuticals and Theravance Biopharma are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk. Immune Pharmaceuticals presently has a consensus price target of $3.00, indicating a potential upside of 138.10%.

    Comment?

  3. Psoriasis medication: what to expectRead the original story

    Thursday Aug 17 | CNN

    This content is selected and managed by the Healthgrades editorial staff and is brought to you by an advertising sponsor. This content is created or selected by the Healthgrades editorial team and is funded by an advertising sponsor.

    Comment?

  4. Cambrex Corporation (CBM) vs. Immune Pharmaceuticals (NASDAQ:IMNP) Head to Head ComparisonRead the original story w/Photo

    Wednesday Aug 16 | IntersportsWire

    Cambrex Corporation and Immune Pharmaceuticals are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations. Cambrex Corporation presently has a consensus price target of $65.67, indicating a potential upside of 23.55%.

    Comment?

  5. Azotemia: Symptoms, types, and treatmentRead the original story w/Photo

    Tuesday Aug 15 | Medical News Today

    The kidneys and the renal system usually filter waste products out of the blood. They also make urine to help eliminate those wastes, along with extra water, from the body.

    Comment?

  6. Head-To-Head Analysis: Immune PharmaceuticalsRead the original story w/Photo

    Friday Aug 11 | IntersportsWire

    Immune Pharmaceuticals and SCYNEXIS are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitabiliy, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. 59.6% of Immune Pharmaceuticals shares are held by institutional investors.

    Comment?

  7. Learn Details of the Global Eczema Treatment MarketRead the original story w/Photo

    Thursday Aug 10 | SBWire

    Eczema, also referred as dermatitis or atopic dermatitis, is a disease which results in inflammation of the skin. Eczema is characterized by rash, red skin, and itchiness.

    Comment?

  8. Cytovia, Inc., Immune Pharma??'s Oncology Subsidiary, Announces...Read the original story

    Wednesday Aug 9 | BioSpace

    Cytovia, the oncology subsidiary of Immune Pharmaceuticals Inc. , a clinical stage biopharmaceutical company, today announced the publication of results showing favorable effects of its lead immunotherapeutic compound CepleneA in cancer. The results of the new article confirm and extend previous findings showing that treatment of mice with CepleneA efficiently reduces the formation of lung melanoma metastases.

    Comment?

  9. Liposome Drug Delivery Market Demand Is Increasing Rapidly in Recent YearsRead the original story w/Photo

    Wednesday Aug 9 | SBWire

    Liposomes are small spherical-shaped artificial vesicles synthesized from phospholipids and cholesterol. They are colloidal carriers and range from 0.01 to 5.0 ?m in diameter.

    Comment?

  10. Comparing Immune PharmaceuticalsRead the original story w/Photo

    Tuesday Aug 8 | IntersportsWire

    Immune Pharmaceuticals and Theravance Biopharma are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitabiliy, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. This is a summary of current recommendations and price targets for Immune Pharmaceuticals and Theravance Biopharma, as provided by MarketBeat.com.

    Comment?

  11. Cambrex Corporation (CBM) versus Immune Pharmaceuticals (NASDAQ:IMNP) Critical AnalysisRead the original story w/Photo

    Tuesday Aug 8 | IntersportsWire

    Cambrex Corporation and Immune Pharmaceuticals are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitabiliy, analyst recommendations and institutional ownership. Cambrex Corporation currently has a consensus price target of $65.67, indicating a potential upside of 19.72%.

    Comment?

  12. Imprimis Statement Regarding Curcumin Emulsion FDA MedWatch NoticeRead the original story

    Sunday Aug 6 | BioSpace

    Imprimis has been successful because we place patient safety and compassion for those we serve above all else. Imprimis facilities are regularly inspected by state and federal officials, including the FDA, and our distinguished quality team looks to all regulators as partners in protecting patients, which is critical for the long-term success of our business."

    Comment?

  13. CYTOVIA Inc., IMMUNE Pharma's Oncology Subsidiary, Announces the...Read the original story

    Monday Aug 7 | Customer Interaction Solutions

    CYTOVIA Inc., IMMUNE Pharma's Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene in Chronic Myeloid Leukemia CYTOVIA Inc., IMMUNE Pharma's Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene in Chronic Myeloid Leukemia Cytovia, the oncology subsidiary of Immune Pharmaceuticals , a clinical stage biopharmaceutical company, today announced the publication of new results supporting the benefits of its lead compound Ceplene . In parallel, Cytovia has filed a world-wide patent to protect the use of Ceplene in CML.

    Comment?

  14. Cytovia, Inc., Immune Pharma??'s Oncology Subsidiary, Announces The...Read the original story

    Sunday Aug 6 | BioSpace

    Cytovia, the oncology subsidiary of Immune Pharmaceuticals , a clinical stage biopharmaceutical company, today announced the publication of new results supporting the benefits of its lead compound CepleneA . In parallel, Cytovia has filed a world-wide patent to protect the use of CepleneA in CML.

    Comment?

  15. Global Outlook for Liposome Drug Delivery Market by Key Trends and Analysis 2025Read the original story w/Photo

    Friday Aug 4 | SBWire

    Liposomes are small spherical-shaped artificial vesicles synthesized from phospholipids and cholesterol. They are colloidal carriers and range from 0.01 to 5.0 ?m in diameter.

    Comment?

  16. Immune Pharmaceuticals (IMNP) versus Theravance Biopharma (TBPHV) Head to Head AnalysisRead the original story w/Photo

    Friday Aug 4 | Daily Political

    Immune Pharmaceuticals and Theravance Biopharma are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitabiliy. 60.1% of Immune Pharmaceuticals shares are held by institutional investors.

    Comment?

  17. 10 facts about fungiRead the original story w/Photo

    Friday Aug 4 | OUPblog

    Very Short Introductions series combines a small format with authoritative analysis and big ideas for hundreds of topic areas. Written by our expert authors, these books can change the way you think about the things that interest you and are the perfect introduction to subjects you previously knew nothing about.

    Comment?

  18. Inhibition of Bcl-xL prevents pro-death actions of I"N-Bcl-xL at the...Read the original story

    Friday Aug 4 | Cell Death and Differentiation

    Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity Correspondence: EA Jonas, Department Internal Medicine, Section of Endocrinology, Yale University School of Medicine, PO Box 208020, New Haven, CT 06520, USA. Tel: 203 785 3087; Fax: 203 785 6015; E-mail: [email protected] ABT-737 is a pharmacological inhibitor of the anti-apoptotic activity of B-cell lymphoma-extra large protein; it promotes apoptosis of cancer cells by occupying the BH3-binding pocket.

    Comment?

  19. Clinical ImplicationsRead the original story

    Jul 1, 2017 | Circulation

    Endothelin receptor antagonists are an established treatment for pulmonary arterial hypertension and scleroderma digital ulceration, and they show promise in chronic kidney disease and resistant hypertension. Their use may be limited by salt and water retention.

    Comment?

  20. Liposome Drug Delivery Market Analysis and Forecast by 2025Read the original story w/Photo

    Thursday Aug 3 | PR-inside.com

    Transparency Market Research Report Added "Liposome Drug Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025" Liposomes are small spherical-shaped artificial vesicles synthesized from phospholipids and cholesterol. They are colloidal carriers and range from 0.01 to 5.0 I1 4m in diameter.

    Comment?